Cargando…
Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men
Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571963/ https://www.ncbi.nlm.nih.gov/pubmed/23418527 http://dx.doi.org/10.1371/journal.pone.0056151 |
_version_ | 1782259245328105472 |
---|---|
author | Durussel, Jérôme Daskalaki, Evangelia Anderson, Martin Chatterji, Tushar Wondimu, Diresibachew H. Padmanabhan, Neal Patel, Rajan K. McClure, John D. Pitsiladis, Yannis P. |
author_facet | Durussel, Jérôme Daskalaki, Evangelia Anderson, Martin Chatterji, Tushar Wondimu, Diresibachew H. Padmanabhan, Neal Patel, Rajan K. McClure, John D. Pitsiladis, Yannis P. |
author_sort | Durussel, Jérôme |
collection | PubMed |
description | Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. METHODS: 19 trained men received rHuEpo injections of 50 IU•kg(−1) body mass every two days for 4 weeks. Hb(mass) was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. [Image: see text] O(2 max) and 3,000 m time trial performance were measured pre, post administration and at the end of the study. RESULTS: Relative to baseline, running performance significantly improved by ∼6% after administration (10∶30±1∶07 min:sec vs. 11∶08±1∶15 min:sec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (10∶46±1∶13 min:sec, p<0.001), while [Image: see text] O(2 max) was also significantly increased post administration (60.7±5.8 mL•min(−1)•kg(−1) vs. 56.0±6.2 mL•min(−1)•kg(−1), p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min(−1)•kg(−1), p = 0.021). Hb(mass) was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg(−1) vs. 12.7±1.2 g•kg(−1), p<0.001). The rate of decrease in Hb(mass) toward baseline values post rHuEpo was similar to that of the increase during administration (−0.53 g•kg(−1)•wk(−1), 95% confidence interval (CI) (−0.68, −0.38) vs. 0.54 g•kg(−1•)wk(−1), CI (0.46, 0.63)) but Hb(mass) was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg(−1), p<0.001). CONCLUSION: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated [Image: see text] O(2 max) and Hb(mass). |
format | Online Article Text |
id | pubmed-3571963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35719632013-02-15 Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men Durussel, Jérôme Daskalaki, Evangelia Anderson, Martin Chatterji, Tushar Wondimu, Diresibachew H. Padmanabhan, Neal Patel, Rajan K. McClure, John D. Pitsiladis, Yannis P. PLoS One Research Article Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hb(mass)) and maximal oxygen uptake ([Image: see text] O(2 max)). PURPOSE: This study defined the time course of changes in Hb(mass), [Image: see text] O(2 max) as well as running time trial performance following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual improvements in running performance in the field. METHODS: 19 trained men received rHuEpo injections of 50 IU•kg(−1) body mass every two days for 4 weeks. Hb(mass) was determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. [Image: see text] O(2 max) and 3,000 m time trial performance were measured pre, post administration and at the end of the study. RESULTS: Relative to baseline, running performance significantly improved by ∼6% after administration (10∶30±1∶07 min:sec vs. 11∶08±1∶15 min:sec, p<0.001) and remained significantly enhanced by ∼3% 4 weeks after administration (10∶46±1∶13 min:sec, p<0.001), while [Image: see text] O(2 max) was also significantly increased post administration (60.7±5.8 mL•min(−1)•kg(−1) vs. 56.0±6.2 mL•min(−1)•kg(−1), p<0.001) and remained significantly increased 4 weeks after rHuEpo (58.0±5.6 mL•min(−1)•kg(−1), p = 0.021). Hb(mass) was significantly increased at the end of administration compared to baseline (15.2±1.5 g•kg(−1) vs. 12.7±1.2 g•kg(−1), p<0.001). The rate of decrease in Hb(mass) toward baseline values post rHuEpo was similar to that of the increase during administration (−0.53 g•kg(−1)•wk(−1), 95% confidence interval (CI) (−0.68, −0.38) vs. 0.54 g•kg(−1•)wk(−1), CI (0.46, 0.63)) but Hb(mass) was still significantly elevated 4 weeks after administration compared to baseline (13.7±1.1 g•kg(−1), p<0.001). CONCLUSION: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated [Image: see text] O(2 max) and Hb(mass). Public Library of Science 2013-02-13 /pmc/articles/PMC3571963/ /pubmed/23418527 http://dx.doi.org/10.1371/journal.pone.0056151 Text en © 2013 Durussel et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Durussel, Jérôme Daskalaki, Evangelia Anderson, Martin Chatterji, Tushar Wondimu, Diresibachew H. Padmanabhan, Neal Patel, Rajan K. McClure, John D. Pitsiladis, Yannis P. Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men |
title | Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men |
title_full | Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men |
title_fullStr | Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men |
title_full_unstemmed | Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men |
title_short | Haemoglobin Mass and Running Time Trial Performance after Recombinant Human Erythropoietin Administration in Trained Men |
title_sort | haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571963/ https://www.ncbi.nlm.nih.gov/pubmed/23418527 http://dx.doi.org/10.1371/journal.pone.0056151 |
work_keys_str_mv | AT durusseljerome haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT daskalakievangelia haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT andersonmartin haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT chatterjitushar haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT wondimudiresibachewh haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT padmanabhanneal haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT patelrajank haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT mcclurejohnd haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen AT pitsiladisyannisp haemoglobinmassandrunningtimetrialperformanceafterrecombinanthumanerythropoietinadministrationintrainedmen |